Jump to content

Genedata Selector
Open Forum Registration

Genedata Selector is committed to facilitating the exchange of knowledge and discussion of best practices of next-generation sequencing (NGS) for cell and gene therapy development, biosafety testing and cell line development. To this end, Genedata Selector regularly hosts exclusive community-building industry workshops with leading biopharmaceutical companies, featuring expert presentations and discussions on key industry challenges and opportunities to learn and share perspectives.

Our Open Forums have brought together biopharma speakers from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, FUJIFILM, Johnson & Johnson, Lonza, MSD, Octapharma, Pfizer, Sanofi, Sarepta Therapeutics, and Umoja to share perspectives across a broad range of topics. Discussions have covered GxP validation‑ready NGS workflows, method design, qualification, and data workflows for compliant deployment in regulated environments, as well as NGS‑based approaches for biosafety testing and quality control of biologics. Additional contributions addressed in‑house sequencing strategies, product development and characterization for cell and gene therapies, AAV vector production and characterization, and NGS‑based methods supporting biosafety testing and cell line development.

Register Your Interest in Our Next Events

Read About Our Meetings

Biosafety
Cell Line Development
Cell and Gene Therapy
GMP and Regulations

The Open Forum was a great opportunity to share our work and participate in the panel discussion.

Past Open Forum Speaker

A good range of projects looking at different aspects of CGT development.

Past Open Forum Attendee

I would also like to support the continuation of the Open Forum events and talk more about the internal status of using NGS for QC. I have been very impressed with the progress of Selector, especially for biosafety.

Past Open Forum Attendee

Excellent presentations that helpfully introduced the topic and then became more specific as the webinar progressed.

Past Open Forum Attendee

The open panel discussion and Q&A sessions provided very good insight into how the NGS field is currently supporting CGT development.

Past Open Forum Attendee

A detailed explanation of the different pipelines used by the speakers in their companies.

Past Open Forum Attendee

I found the Open Forum very useful. The demo was very nice and I liked the user interface of Selector. Selector can be used in a validate environment, which is a great advantage.

Past Open Forum Attendee

The Open Forum was a great start to getting to know the Selector software. I will definitely be attending future events.

Past Open Forum Attendee

An excellent variety of speakers and panelists.

Past Open Forum Attendee

Disclaimer: The purpose of our meeting and discussions is to initiate a pre-competitive R&D collaboration and to discuss Next-Generation Sequencing (NGS) in gene and cell therapy, multi-attribute method (MAM) approaches, and biosafety. We consider our discussions to be pre-competitive in nature, as the best practices can be used very widely in the industry. Please keep the conversation on this topic and refrain from raising issues that could be considered anti-competitive under antitrust and competition laws, such as pricing.